<DOC>
	<DOC>NCT00227279</DOC>
	<brief_summary>This trial is performed to assess the efficacy and safety of the ALK Grass tablet for treatment of grass pollen induced rhinoconjunctivitis (hayfever).</brief_summary>
	<brief_title>A Trial of the ALK Grass Tablet in Subjects With Hayfever</brief_title>
	<detailed_description />
	<criteria>Eligibility Criteria: A history of grass pollen induced rhinoconjunctivitis Positive skin prick test to grass Positive specific IgE to grass</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Grass pollen allergy</keyword>
	<keyword>Hayfever</keyword>
	<keyword>Allergen immunotherapy</keyword>
	<keyword>Specific immunotherapy</keyword>
</DOC>